Watch for aleniglipron body composition, T2DM and SWITCH data expected in Q4 2026, which could de-risk the Phase 3 program. ACCG-2671 MAD data in 1H 2027 is the next major pipeline catalyst.
Drugs in focus
GPCR drug pipeline →ACCG-2671
● Neutral Named in this press release- Impact
- Phase
- Phase 1/2a
- Time to market
- Given that ACCG-2671 is still in Phase 1/2a, potential approval is likely many years away (probably 2029-2031 at the earliest), assuming successful clinical development.
- Next catalyst
- None dated
What to watchACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $21.73entry
- T+1 · 6d ago −3.59%α −4.91% · $20.95
- T+4 · todayOpen
- T+5 · in 9h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3 2025, driven by increased R&D spending as the Phase 3 ACCOMPLISH program for aleniglipron initiates. Cash burn was $60M sequentially, leaving $1.2B in cash expected to fund operations through 2028. Key catalysts include aleniglipron supplementary data in Q4 2026 and ACCG-2671 MAD data in 1H 2027.
Key Facts
- Net loss of $144.8M in Q3 2026 vs $65.7M in Q3 2025
- Cash, cash equivalents and short-term investments of $1.2B as of Sep 30, 2026, down from $1.3B at Jun 30, 2026
- Phase 3 ACCOMPLISH program for aleniglipron initiated in August 2026; topline data expected in 2H 2028
- R&D expenses $134.6M in Q3 2026 vs $59.0M in Q3 2025
- ACCG-2671 MAD trial dosing underway; topline data expected in 1H 2027
Financial Impact
Net loss widened by $79.1M YoY; cash burn of ~$60M in Q3; $1.2B cash runway through 2028
Risk Factors
- Cash burn rate is accelerating with Phase 3 costs; $1.2B may not cover pre-commercialization manufacturing costs
- Aleniglipron Phase 3 data not expected until 2H 2028, leaving a long period without major catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398932 |
Track record
10 reports on GPCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $21.73 Now $18.57 −14.54% settles Feb 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $19.08 Now $18.57 −2.67% settles Feb 3
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $43.30 to $47.34 Now $18.57 +57.11% ▼ −9.33% −4.93% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $39.10 to $49.64 Now $18.57 −52.51% ▲ +26.96% +22.12% vs SPY
- Apr 27, 202629w ago Press Release Neutral 2/10 Entry $43.56 to $50.80 Now $18.57 −57.37% ▲ +16.62% +12.63% vs SPY
- Apr 15, 202630w ago 8-K Neutral 3/10 Entry $54.25 to $53.36 Now $18.57 −65.77% ▼ −1.64% −9.78% vs SPY
- Mar 16, 202635w ago Press Release Bullish 8/10 Entry $56.65 to $37.77 Now $18.57 −67.22% ▼ −33.33% −43.81% vs SPY
- Feb 28, 202637w ago Institutional Cluster Mixed 6/10 Entry $62.90 to $39.58 Now $18.57 −70.48% ▼ −37.07% −46.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers